National Cancer Institute-supported chemotherapy-induced peripheral neuropathy trials: outcomes and lessons.

Author(s): Majithia N,  Temkin SM,  Ruddy KJ,  Beutler AS,  Hershman DL,  Loprinzi CL

Journal: Support Care Cancer

Date: 2016 Mar

Major Program(s) or Research Group(s): COPTRG, SXMGMT

PubMed ID: 26686859

PMC ID: PMC5078987

Abstract: Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most common and debilitating complications of cancer treatment. Due to a lack of effective management options for patients with CIPN, the National Cancer Institute (NCI) sponsored a series of trials aimed at both prevention and treatment. A total of 15 such studies were approved, evaluating use of various neuro-modulatory agents which have shown benefit in other neuropathic pain states. Aside from duloxetine, none of the pharmacologic methods demonstrated therapeutic benefit for patients with CIPN. Despite these disappointing results, the series of trials revealed important lessons that have informed subsequent work. Some examples of this include the use of patient-reported symptom metrics, the elimination of traditional--yet unsubstantiated--practice approaches, and the discovery of molecular genetic predictors of neuropathy. Current inquiry is being guided by the results from these large-scale trials, and as such, stands better chance of identifying durable solutions for this treatment-limiting toxicity.